SUMMARY A large number and variety of compounds (acetylcholine, adenosine diphosphate, adenosine triphosphate, arachidonic acid, bradykinin, Ca 2+ ionophores, calcitonin gene-related peptide, histamine, hydralazine, substance P, thrombin, and vasoactive intestinal polypeptide) have been shown to relax arterial smooth muscle indirectly. The endothelium in muscular arteries from several species appears to have receptors for these vasodilators. Binding of one of these compounds to its endothelial receptors results in the release (and presumably synthesis) of substance(s) that act on arterial smooth muscle to cause relaxation. The name endothelium-derived relaxing factor (EDRF) has been proposed for the substance or substances responsible for inhibition of contraction. Studies to determine additivity of endothelium-dependent relaxing agents and sensitivity of EDRF-mediated responses to a variety of inhibitors suggest that a single factor or a single common mechanism induces relaxation of vascular smooth muscle. Pharmacological studies have been equivocal with regard to the postulated involvement of phospholipases or arachidonic acid and to the suggestion that EDRF is an oxidative, noncydooxygenase product of arachidonate. Experiments on transfer of EDRF and reversal of endothelium-dependent relaxation consistently indicate that EDRF is quite labile. There is convincing evidence that EDRF activates smooth muscle guanylate cyclase, which results in an increase in intracellular cyclic guanosine 3',5'-monophosphate levels. The stimulation of guanylate cyclase by EDRF provides a valuable and sensitive parameter for studies with arteries as well as cells in culture. At present, the identity of EDRF and its role in cardiovascular homeostasis are unknown. 
O NE of the first reports of endothelium-dependent vasodilation was published in 1980' and addressed the vascular responses to acetylcholine (Ach). In preparations with intact endothelium, low concentrations of Ach (10~8-10~6 M) were found to relax precontracted rabbit aorta, while higher concentrations (>10~6 M) exerted direct contractile effects independent of the presence of endothelium.
1 It was also postulated that the endothelium released a factor that acted on arterial smooth muscle to promote relaxation of muscle tone. Evidence for transfer of a relaxing factor from endothelium to muscle was obtained by placing the intima of an intact piece of aorta against the lumenal surface of a bioassay aortic strip with no endothelium, which demonstrated that dilation in response to Ach necessitated the donor endothelium. Prostacyclin was an immediate candidate for the factor; however, endothelium-dependent vasodilation was obtained in arteries (i.e., rabbit thoracic aorta) that do not respond to prostacyclin and the response was not altered by treatment with cyclooxygenase inhibitors (nonsteroidal antiinflammatory agents).' The term endothelium-derived relaxing factor (EDRF) was proposed for the substance that induces smooth muscle relaxation. 2 Since the initial reports, numerous investigators have confirmed that the endothelium is requisite for cholinergic-induced vasodilation in a number of arterial preparations and an extensive list of other endothelium-dependent vasoactive substances has been generated (for reviews, seerefs. 2, 3, and Table 1 ). The list of vasodilators includes potential physiological dilators such as Ach, adenosine diphosphate, adenosine triphosphate (ATP), bradykinin, substance P, thrombin, calcitonin gene-related peptide and histamine, as well as pharmacological vasodilators such as high concentrations of arachidonic acid, other saturated and unsaturated fatty acids, hydralazine, A23187, and melittin (see Table 1 for references). The capacity to produce EDRF has been demonstrated in numerous species including humans (Table 1) . Production and release appears to be a property primarily of arterial endothelium, although it has been documented in some venous preparations.
u Most of the arterial preparations studied have been conduit arteries, though some work END0THEL1UM-DER1VED VASCULAR RELAXING FACTOR/Peac/i et al.
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has been done in vascular beds, which suggests that resistance vessels also may produce or respond to EDRF b -7 Despite the seemingly universal nature of the factor, a given agent does not necessarily relax all arterial preparations (see Table 1 ). In the absence of any direct evidence, this finding probably reflects the endothelium receptor complement for various vasodilators. In addition, not all cholinergic vasodilation may be endothehum dependent; Brayden and Bevan 33 have reported the existence of direct muscarinic neurogenic vasodilation in the postauncular artery in the cat.
A variety of techniques has been used to remove the endothelium, with success verified by silver staining followed by light microscopy 1 " l2 l4 or by scanning 22 and transmission electron microscopy l4 These techniques encompass 1) mechanical or physical (e.g., rubbing, scraping, insertion of suture or swab through the lumen, or balloon cathetenzation),' l2 l4 " 2) enzymatic, 1 and 3) chemical (perfusion with hypotonic medium, 36 exposure to p-bromophenacyl bromide 2 ) methods. When harsh measures are used to remove the endothehum, several layers of smooth muscle cells or much of the medial layer may also be damaged and alter responses to vasoconstrictors as well as endothelium-independent vasodilators.
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Involvement of Arachidonic Acid
Among the first observations regarding endothelium-dependent vasodilation by Ach was the rapid and complete reversal of relaxation by eicosatrayenoic acid (ETYA), an inhibitor of cyclooxygenase and lipoxygenase, and quinacrme, a phospholipase inhibitor. However, there was no inhibitory effect with cyclooxygenase inhibitors such as indomethacin ' These basic observations have been confirmed several times in rabbit aorta, 4 ' and similar observations have been made in other species and preparations (see Table 1 be present in vascular endothelium/ 1 " and, using cytochrome P-450 inhibitors, we have provided indirect evidence that such a pathway could be active in the production of an EDRF '" Validation of the pathway requires more direct evidence regarding the activity of cytochrome P-450 and its ability to metabolize arachidonate in preparations shown to have endothehumdependent relaxation responses Despite the evidence summarized above, the role of phosphohpase activation and arachidonic acid release in the production and release of EDRF is difficult to assess with certainty. Activation of phospholipase with mehttm results in endothelium-dependent relaxation in rabbit thoracic aorta (Peach MJ, Loeb AL, unpublished results, 1985) 26 Phospholipase inhibitors such as qumaenne and p-bromophenacylbromide block or reverse vasodilation in response to melittin , however, quinacrine does not antagonize the response to ATP, bradykinin, or A23187 in rabbit aorta 4 or to ATP and thrombin in canine femoral artery."
Glucocorticoid pretreatment, which has been shown to inhibit phospholipase in other cellular systems," " has not been reported to alter responses to endothelium-dependent vasodilators. In rats treated with dexamethasone for 7 days, we found normal vasodilator response to Mch (Peach MJ, Singer HA, unpublished observation) In addition to arachidonic acid, several other unsaturated and saturated fatty acids (but not ETYA) also promote endothelium-dependent responses,' 1 and it has been suggested that these lipids (including arachidonate) are not precursors but rather promote the synthesis (or release) of EDRF ' It is possible that multiple pathways for EDRF formation exist or even that multiple EDRFs exist, 11 and this could explain the contradictory evidence regarding involvement of phosphohpases and arachidonic acid in the endothelium-dependent response It is also possible that the pharmacological evidence is misleading and that arachidonic acid is not directly involved in the relaxation responses. Strictly speaking, the endothelium is known to release the vasodilators prostacyclin s n 2I -12 and platelet-activating factor, 5 * both of which should be considered known EDRFs
Maximal doses of the various endothelium-dependent dilators are not additive to each other or to the Ca 2+ lonophore A23187, 57 which has the greatest maximum efficacy of all the compounds that induce EDRF release.
22 " The response to A23187 is additive to that obtained with a maximum concentration of Ach or ATP, but only to the level of maximal relaxation induced by A23187 alone. 57 These addition studies are consistent with release of either a common factor or multiple factors with a common mechanism of action The varied maximum efficacies for relaxation among the dilator substances that act through the endothelium probably reflect the magnitude of receptor-mediated Ca 2+ influx and therefore the amount of EDRF produced (or released) The efficacy of A23187 probably is determined by the maximum rate at which EDRF can be released or reflects the ultimate capacity of EDRF to induce smooth muscle relaxation.
Antioxidants and nonspecific radical scavengers (e g , dithiothreitol, cysteine, phenidone, tetrahydroborate, phenylhydrazine, hydroquinone, resorcinol, butylated hydroxytoluene, a-tocopherols) inhibit endothelium-dependent relaxation l(t 38 45 Coupled with the ETYA and NDGA data, this finding constituted the basis for the postulate that EDRF is a hydroperoxy fatty acid or a hydroxy fatty acid.
111 Recently, Griffith et al "* reported data from a series of superfusion transfer experiments that bring into question the actual mechanism for the inhibitory action of NDGA and other lipoxygenase inhibitors with antioxidant activity. These investigators found that several antioxidant or free radical scavenger compounds (cysteine, dithiothreitol, phenylhydrazine, hydroquinone, phenidone, and NDGA) inactivated EDRF in solution and did not need to act on the endothelium to inhibit endotheliumdependent relaxation Their studies involved perfusion of a large (7-8 cm) segment of intact rabbit aorta that was connected by a cannula to a bioassay coronary artery denuded of endothelium By varying the distance for transfer between donor endothelium and bioassay ring, they estimated a half-life for EDRF in solution of 6.3 ± 0.6 seconds. Drugs were introduced into the perfusate before or after the aortic segment Agents such as NDGA and phenidone blocked the EDRF response even when added after the endothehal source (aorta) The donor endothelium, therefore, was not exposed to these compounds The series of effective blockers of EDRF identified in this study suggests that EDRF contains a highly reactive carbonyl group (ketone, aldehyde, or lactone). Griffith et al.' 8 proposed that the blocking agents interfered with this chemical group and enhanced the lability of EDRF in solution These agents do inactivate EDRF, but it is unlikely that carbonyl function is involved. Although ascorbate 1-98 these antioxidants have been found to impair the inhibitory actions of hydroquinone on EDRF-induced relaxation (Peach MJ, unpublished observation. 1984) Therefore, ascorbate and metabisulfite may impair an oxidative step that must occur before any reaction between EDRF and compounds such as hydroquinone or resorcinol takes place Such a requisite oxidative step(s) would argue against a straightforward chemical reaction Hemoglobin also has been shown to attenuate EDRF-dependent responses ' Furchgott et al ' suggested that because of its size this heme-containing protein can sequester or inactivate EDRF in solution ' Several of these antioxidants and radical scavengers also may inhibit guanylate cyclase activity, which would result in attenuation of relaxation induced by EDRF
Cyclic GMP and Endothelium-Derived
Relaxing Factor Induced Vascular Smooth Muscle Relaxation In 1983, Rapoport and Murad 8 reported that the accumulation of cyclic guanosine 3',5'-monophosphate (GMP) in rat aorta in response to Ach, histamine, and A23187 was dependent on the endothelium The increase in aortic cyclic GMP levels with sodium nitroprusside or nitroglycenn had no endothelium dependence Other laboratories have confirmed that a variety of endothelium-dependent dilators in other species and arteries stimulate guanylate cyclase in smooth muscle K w Thus, the EDRF released in an intact vessel acts on muscle and cyclic GMP levels increase Regardless of the controversy over the precise role of cyclic GMP in smooth muscle relaxation, 60 6I the exposure of smooth muscle to EDRF is reflected by the change in cyclic GMP concentration Cyclic GMP accumulation therefore represents an important biochemical parameter that reflects the interaction of EDRF with muscle and can be readily exploited in tissue and cell culture studies
Endothelium-Derived Relaxing Factor in
Cultured Cells With cultured endothelium, no specific binding of the muscannic radioligand [-"HJQNB occurs and no detectable vasodilator substance is released into the medium during exposure to Ach; however, rabbit aortic endothelium, either freshly obtained by adhesion to glass covershps or removed after exposure of intact aortic rings to pH]QNB, demonstrates atropine sensitive (specific), saturable binding of the radioligand (Peach MJ, unpublished observation, 1984) Therefore, the muscannic receptor appears to be extremely labile during isolation of endothelial cells, and this receptor is not phenotypically expressed under conditions of endothelial cell culture. In contrast, other receptor types (bradykinin, ATP, adenosine diphosphate) are expressed by cultured endothelium from bovine 62 and porcine aorta. In spite of the presence of functional receptors, transfer experiments from cultured endothelium to cultured smooth muscle or to an arterial ring (strip) without endothelium have failed to demonstrate release of EDRF in response to bradykinin, ATP, and Ach
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However, large concentrations of A23187 have been shown to release substances from cultured cells When endothelial cells are grown on carrier beads, large numbers of cells can be readily placed in a column and superfused In response to A23187, column superfused cells appear to release prostacyclin, ATP, and possibly other compounds, one of which may be EDRF. 21 Recently, we have begun these types of studies using cultured pig aortic endothelium and vascular smooth muscle. In monolayer cultures of porcine aortic endothelium or aortic smooth muscle, Ach did not stimulate cyclic GMP accumulation However, the cultured muscle cells responded to 10 -fl M sodium nitroprusside with a fivefold increase in cyclic GMP. The cultured porcine aortic smooth muscle cells do have receptors for Ach (I'HIQNB binding) and undergo a shape change (contraction) in response to hormones and neurotransmitters; however, cyclic GMP levels did not change in response to muscannic agonists When the two cell types were cultured together and then exposed to either ATP or methacholine. we observed an increase in cyclic GMP levels similar to that seen in aortic ring preparations.* 1 ™ Thus, it appears that the phenotypic expression of EDRF synthesis and release -certainly the presence ot muscannic receptor on endothelium and of the EDRF receptor on muscle cells -requires the presence of both cell types in the culture The addition of endothelial cells to a monolayer culture of smooth muscle for 3 days resulted in a culture that also responded to a cholinergic agonist with an increase in cyclic GMP levels. The rise in cyclic GMP induced by a muscarinic compound could be completely blocked by the presence of ETYA, which suggests EDRF stimulation of guanylate cyclase (Figure 1 ). These recent successes with cultured endothelial cells and EDRF release hold great promise for production of large quantities of the factor for isolation and chemical characterization. With the cultured cells, sustained production by large amounts of endothelium should enhance attempts to trap EDRF with columns (C l8 , ion exchange, hemoglobin Sepharose) or solvents.
Although the identity of EDRF remains unknown, it is clear that the endothelium modulates the ability of arterial smooth muscle to generate and sustain tone by releasing a relaxing factor and that the endothelial cell has receptors for a large number of vasoactive substances. Changes in any of these endothelial receptors or in the capacity of the endothelium to produce and release EDRF or in smooth muscle responsiveness to EDRF could play a major role in diabetic vascular disease, hypertension, vascular spasms, atherosclerosis, or other types of vascular pathophysiology. 
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